OPR - Delayed Quote • USD ALEC Jan 2025 7.500 call (ALEC250117C00007500) Follow 1.7000 0.0000 (0.00%) As of April 16 at 2:20 PM EDT. Market Open. Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for ALEC250117C00007500 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: ALEC Will Alector (ALEC) Report Negative Q1 Earnings? What You Should Know The past five years for Alector (NASDAQ:ALEC) investors has not been profitable The Alector, Inc. (NASDAQ:ALEC) Full-Year Results Are Out And Analysts Have Published New Forecasts What You Need To Know About The Alector, Inc. (NASDAQ:ALEC) Analyst Downgrade Today Q4 2023 Alector Inc Earnings Call Alector, Inc. (NASDAQ:ALEC) Q4 2023 Earnings Call Transcript Alector to Participate in Upcoming Healthcare Conferences Alector Inc (ALEC) Reports Fourth Quarter and Full Year 2023 Financial Results Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Alector to Host Fourth Quarter and Full-Year 2023 Earnings Call Earnings Preview: Alector (ALEC) Q4 Earnings Expected to Decline Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer’s Disease
